The company’s short history, a cautionary tale about investing in the hype around all things Covid, reaches the point of show and tell.
A look at the past week’s Covid winners and losers finds Pfizer, unusually, among the latter.
Record guidance disappoints, so talk once again turns to deals.
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?